Work

Early-phase clinical trials in a pandemic: learning from the response to COVID-19

Year: 2022

Type: article

Source: The Lancet Respiratory Medicine

DOI: 10.1016/s2213-2600(22)00062-5

Authors: Alex Horsley, Chris Brightling, Jane Davies, Ratko Djukanovic, Liam G Heaney, Tracy Hussell, Stefan J Marciniak, Lorcan McGarvey, Joanna C Porter, Thomas Wilkinson, Ling-Pei Ho

Institutions: Manchester Academic Health Science Centre, University of Manchester, University of Leicester, NIHR Leicester Biomedical Research Centre, Royal Brompton & Harefield NHS Foundation Trust, Imperial College London, NIHR Southampton Biomedical Research Centre, University of Southampton, Queen's University Belfast, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Papworth Hospital NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, University College London, University of Oxford, NIHR Oxford Biomedical Research Centre, MRC Human Immunology Unit

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Teva Pharmaceutical Industries, Celgene, Chiesi Farmaceutici, Boehringer Ingelheim, UCB, Genentech

OpenAlex ID: W4282835523

FWCI: 0.244

Cites: 7

Cited by: 3

Related to: 10